Plant Name: Alstonia yunnanensis
Taxonomic Information:
Plant ID: NPO17362
Plant Latin Name: Alstonia yunnanensis
Taxonomy Genus: Alstonia
Taxonomy Family: Apocynaceae
Plant External Links:
NCBI TaxonomyDB:
1905568
Plant-of-the-World-Online:
76608-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRM1; NPSR1; | |
| PTPN1; | |
| PTGES; ALOX12; HSD11B1; | |
| MAPK1; | |
| PTGS1; | |
| CASP1; CASP7; | |
| HIF1A; | |
| ABCB1; | |
| MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | OPRM1 | Mu opioid receptor | P35372 | CHEMBL233 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 7.907E-12 | 8.608E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.600E-10 | 1.272E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.716E-09 | 7.393E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 5.282E-08 | 1.126E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.120E-08 | 1.360E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.678E-08 | 1.360E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.445E-08 | 1.469E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.487E-07 | 1.905E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.876E-07 | 3.132E-04 | ALOX12, CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 3.900E-07 | 3.860E-04 | HIF1A, MAPK1, MAPT, OPRM1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.942E-07 | 8.466E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.455E-06 | 1.980E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, HSD11B1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.993E-06 | 2.805E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0071242; cellular response to ammonium ion | 5.176E-06 | 3.315E-03 | CASP7, MAPK1, OPRM1 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.097E-05 | 5.973E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, HSD11B1, PTGES, PTGS1 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.718E-05 | 8.500E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.017E-09 | 2.239E-07 | CYP2C9, ALOX12, CYP2C19, PTGES, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.412E-09 | 3.979E-07 | HSD11B1, CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.069E-08 | 1.129E-06 | CYP2C9, MAPK1, ALOX12, CYP2C19, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.075E-08 | 3.979E-07 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.827E-07 | 8.496E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.808E-07 | 8.894E-06 | HSD11B1, CYP2C9, CYP1A2, CYP3A4 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.303E-06 | 8.409E-05 | HSD11B1, CYP2C9, CYP1A2, ALOX12, CYP2C19, CYP3A4, PTGS1, PTGES |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.582E-05 | 3.184E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.831E-05 | 2.541E-04 | HSD11B1, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 3.969E-05 | 4.406E-04 | CASP7, CASP1, MAPK1 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 4.330E-04 | 4.369E-03 | CASP7, MAPK1, MAPT |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
| NA: NA | Miosis during ocular surgery | NA | PTGS1; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
| NA: NA | Rheumatold arthritis | NA | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
